Grab some. New data presents. AACR 103rd Annual Meeting -- Saturday, March 31 to Wednesday, April 4, 2012 26-Mar-12 04:38 pm
American Association for Cancer Research (AACR) 103rd Annual Meeting -- Saturday, March 31 to Wednesday, April 4, 2012
Three abstracts discussing translational research findings on Cyclacel's sapacitabine, currently in a Phase 3 clinical study, and two abstracts discussing Cyclacel's selective PLK1 and Aurora A inhibitors, currently in preclinical development, have been selected for presentation at the AACR 103rd Annual Meeting in Chicago, IL.
The abstracts can be accessed through the AACR website, www.aacr.org. Abstract titles are provided below. Please note that according to AACR policy, all data are embargoed until the time of presentation.
Sapacitabine:
"DNA repair defects enhance tumor cell sensitivity to sapacitabine"
Date/Time: Wednesday, April 4, 2012, 8:00 AM -- 12:00 PM CDT
Abstract Number: 5666
"Mechanism-based combinations of agents impacting the homologous recombination and nucleotide excision repair pathways"*
Date/Time: Wednesday, April 4, 2012, 8:00 AM -- 12:00 PM CDT
Abstract Number: 5667
"Patient AML cells and AML cell lines are highly sensitive to CNDAC, the active form of sapacitabine"*
Date/Time: Tuesday, April 3, 2012, 1:00 PM -- 5:00 PM CDT
Abstract Number: 4668
Polo-like kinase 1 (Plk1):
"Potent and selective small molecule inhibitors of polo-like kinase 1: Biological characterization"
Date/Time: Monday, April 2, 2012, 1:00 PM -- 5:00 PM CDT
Abstract Number: 2814
Aurora Kinase A:
"The aurora kinase inhibitor CYC3 synergizes with low concentrations of paclitaxel in pancreatic cancer cells in vitro"
Date/Time: Monday, April 2, 2012, 8:00 AM -- 12:00 PM CDT
Abstract Number: 1924
Share This Post:
   
*****I am writing drunk***** | |
|
204.01
